101
|
Hurtado A, García-Donas J, Garrigos L, Laínez N, Redondo A, Cueva JF, Santaballa A, Rubio MJ, Palacio I, Bover I, Lopez-Guerrero JA, Prieto M, Garcia-Casado Z, Hernando Polo S, Romero N, Grande E. Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.tps5626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
102
|
Redondo A, Cruz J, Lopez-Pousa A, Barón F. SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013. Clin Transl Oncol 2013; 15:1037-43. [DOI: 10.1007/s12094-013-1087-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Accepted: 07/16/2013] [Indexed: 12/01/2022]
|
103
|
González Martín A, Redondo A, Jurado M, De Juan A, Romero I, Bover I, Del Campo JM, Cervantes A, García Y, López-Guerrero JA, Mendiola C, Palacios J, Rubio MJ, Poveda Velasco A. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol 2013; 15:509-25. [PMID: 23468275 PMCID: PMC3695314 DOI: 10.1007/s12094-012-0995-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2012] [Accepted: 12/21/2012] [Indexed: 01/23/2023]
Abstract
In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first "Treatment Guidelines in Ovarian Cancer" were developed and then published in Clinical and Translational Oncology by Poveda Velasco et al. (Clin Transl Oncol 9(5):308-316, 2007). Almost 6 years have elapsed and over this time, we have seen some important developments in the treatment of ovarian cancer. Significant changes were also introduced after the GCIG-sponsored 4th Consensus Conference on Ovarian Cancer by Stuart et al. (Int J Gynecol Cancer 21:750-755, 2011). So we decided to update the treatment guidelines in ovarian cancer and, with this objective, a group of investigators of the GEICO group met in February 2012. This study summarizes the presentations, discussions and evidence that were reviewed during the meeting and during further discussions of the manuscript.
Collapse
|
104
|
Campelo MD, Martín A, Rojas S, Redondo A, Labrador J, López-Corral L, Sánchez-Guijo F, Cañizo M. P-215 The use of 5-azacitidine in allogeneic hematopoietic cell transplantation: A single center experience. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70262-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
105
|
Redondo A, Comas M, Macià F, Ferrer F, Murta-Nascimento C, Maristany MT, Molins E, Sala M, Castells X. Inter- and intraradiologist variability in the BI-RADS assessment and breast density categories for screening mammograms. Br J Radiol 2012; 85:1465-70. [PMID: 22993385 DOI: 10.1259/bjr/21256379] [Citation(s) in RCA: 107] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE The aim of this study was to evaluate reader variability in screening mammograms according to the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) assessment and breast density categories. METHODS A stratified random sample of 100 mammograms was selected from a population-based breast cancer screening programme in Barcelona, Spain: 13 histopathologically confirmed breast cancers and 51 with true-negative and 36 with false-positive results. 21 expert radiologists from radiological units of breast cancer screening programmes in Catalonia, Spain, reviewed the mammography images twice within a 6-month interval. The readers described each mammography using BI-RADS assessment and breast density categories. Inter- and intraradiologist agreement was assessed using percentage of concordance and the kappa (κ) statistic. RESULTS Fair interobserver agreement was observed for the BI-RADS assessment [κ=0.37, 95% confidence interval (CI) 0.36-0.38]. When the categories were collapsed in terms of whether additional evaluation was required (Categories III, 0, IV, V) or not (I and II), moderate agreement was found (κ=0.53, 95% CI 0.52-0.54). Intra-observer agreement for BI-RADS assessment was moderate using all categories (κ=0.53, 95% CI 0.50-0.55) and substantial on recall (κ=0.66, 95% CI 0.63-0.70). Regarding breast density, inter- and intraradiologist agreement was substantial (κ=0.73, 95% CI 0.72-0.74 and κ=0.69, 95% CI 0.68-0.70, respectively). CONCLUSION We observed a substantial intra-observer agreement in the BI-RADS assessment but only moderate interobserver agreement. Both inter- and intra-observer agreement in mammographic interpretation of breast density was substantial. Advances in knowledge Educational efforts should be made to decrease radiologists' variability in BI-RADS assessment interpretation in population-based breast screening programmes.
Collapse
|
106
|
Broto JM, Del Muro XG, Lopez-Pousa A, De Penas RL, Maurel J, Cubedo R, Redondo A, Martinez-Trufero J, Jurado JC, Poveda A. Randomized, Open, Prospective, Phase II Clinical Trial of Doxorubicin (DOXO) vs. Trabectedin Plus Doxo in the First-Line Treatment of Patients (PTS) with Advanced Non-Operable and/or Metastatic Soft Tissue Sarcomas (STS): Geis-20 Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34065-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
107
|
Barriuso J, Moreno V, Coronado M, Galicia I, Soria I, de Castro J, Belda-Iniesta C, Martinez Marín V, Custodio A, Redondo A, Lamarca A, Hindi N, Subiza JL, Frias J, Feliu J, Carcas A. Phase I trial in advanced refractory solid tumors of the new drug first-in-class PDM08. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e13085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13085 Background: PDM08 is a new active compound with antitumor activity in different cancer models. It is a synthetic derivative of the pyroglutamic acid. The lack of direct effect on tumour cells and antitumor activity in immunodeficient models indicates an immune response mediated mechanism. Toxicology and pharmacology preclinical studies showed a favourable safety profile, confirmed by a single-dose placebo controlled healthy volunteer phase I trial. Methods: A single institution open label phase I study was designed (NCT01380249). PDM08 was administered twice a week for four-week cycles. Initially an accelerate escalation phase was chosen with cohorts of 2 patients who after completing the safety period (2 weeks after last dose) had the possibility of escalate to the next dose level if no grade ≥ 2 toxicity and no progressive disease was observed. After 4 cohorts without meaningful toxicity, this design was amended to open new dose levels after a two-week period of treatment completed by the last patient of the cohort if no grade ≥ 2 toxicity was found. The trial was approved by the Ethics Committee and the Spanish Drug Agency. Extensive pharmacokinetic (PK) and pharmacodynamic (PD) data including serum cytokines, lymphoid subpopulations and immunoglobulins are collected. Preliminary efficacy was evaluated by PET-CT. Results: Since July 2011, 10 patients (pts) were recruited into 6 different dose levels (2pts were escalated) ranged from 0.560 mg to 14 mg. Pt characteristics were: female-male ratio 1:1. Median age: 67 (47-76). ECOG 0: 6 pts. 8 pts had colorectal cancer, 1 lung adenocarcinoma and 1 ovarian carcinoma. Median of previous treatments was 3 ranged 2 to 5. 3 pts presented G1 headache. No Dose Limiting Toxicities were found. Preliminary outcome data showed: best response stable disease for 4 patients, 2 of them being stable for 12 weeks. After 40 target lesions evaluated by PET-CT 6 (15%) showed a reduction in the maximum Standard Uptake Value (SUV) of 18-FDG. Conclusions: PDM08 is the first compound of a new class of drugs that can be dose-escalated safely in an accelerated manner and has promising activity. Last patient will be included in March 2012 so final data for toxicity, PK, PD and efficacy will be provided at the meeting.
Collapse
|
108
|
Couloigner V, Sterkers O, Redondo A, Rey A. Brain Abscesses of Ear, Nose, and Throat Origin: Comparison between Otogenic and Sinogenic Etiologies. Skull Base Surg 2011; 8:163-8. [PMID: 17171060 PMCID: PMC1656703 DOI: 10.1055/s-2008-1058177] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
This retrospective study analyzed 29 cerebral abscesses of ear, nose, and throat (ENT) origin. The mean follow-up of patients was 37 months. ENT etiologies included 45% otitis media (n = 13), 48% sinusitis (n = 14), and 7% ethmoidal sinus tumors (n = 2). Thirty-eight percent (n = 5) of otogenic abscesses occurred within 15 days after a mastoidectomy. Sinogenic abscesses were never due to surgery but were associated in 31% of cases (n = 5) with anterior skull base defects. The main locations of otogenic abscesses were the temporal lobe (54%; n = 7) and the cerebellum (23%; n = 3), whereas sinogenic abscesses were located in the frontal lobe in 75% of cases (n = 12). Because of this location, sinogenic abscesses were less symptomatic than otogenic ones and had greater size and encapsulation at the time of diagnosis. Thus, they required longer antibiotic treatment (p = 0.05) and more numerous surgical drainages (p = 0.02). Bacteriologic abscesses samples were positive in 90% of cases. Bacteria found in brain abscesses were different from the ones found in ENT samples in 62% of cases. Thus, the results of ENT bacteriologic samples were not helpful for choosing adequate antibiotic agents in case of negative brain abscess samples. Although mortality was not significantly higher in otogenic abscesses (31%; n = 4) than in sinogenic ones (6%; n = 1, p = 0.08), otogenic abscesses appeared more threatening. Indeed, they represented 80% (n = 4) of lethal cases and encompassed more clinical or radiological prognosis pejorative factors than sinogenic ones (p = 0.006). In conclusion, higher danger of otogenic abscesses mainly resulted both from their temporal or cerebellous locations and from the bacteria that were more frequently resistant to antibiotics.
Collapse
|
109
|
Ojeda B, Casado A, Tibau A, Redondo A, Beltran M, Garcia-Martinez E, Santaballa A, Pardo B, Lianes P, Bover I, Garcia-Donas J, Churruca CM, Cueva JF, Sanchez-Heras AB, Gordon-Santiago MM, Arcusa Lanza A, Lopez-Rodriguez A, Caballero C, Ortega-Izquierdo ME, González-Martín A. Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
110
|
Pinto A, Redondo A, Zamora P, Castelo B, Espinosa E. Predictors for response to chemotherapy and survival in locally advanced breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
111
|
Rubió J, Martinez-Trufero J, Lopez-Pousa A, Garcia del Muro X, Fra J, Redondo A, Lainez N, Poveda A, Casado A, Valverde CM, De Juan A, Sevilla I, Andres R, Cruz J, Safont MJ, Martin Broto J, Garcia-Albeniz X, Maurel J. Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
112
|
Abdennadher M, Goutagny S, Colomban JM, Redondo A. Méningiome intraosseux lytique primitif : à propos d’un cas. Neurochirurgie 2010. [DOI: 10.1016/j.neuchi.2010.10.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
113
|
Mendiola M, Barriuso J, Redondo A, Sánchez-Navarro I, Miguel-Martín M, Madero R, Hernández A, Espinosa E, De Santiago J, Hardisson D. 484 Angiogenesis-related gene profiles with predictive value in advanced ovarian carcinoma (AOC). EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72191-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
114
|
Gonzalvez ML, Diaz N, Redondo A, Calvo EG, Illarramendi JJ, Munarriz B, Del Campo J, Castellanos Diez J, Santaballa A, Lopez-Vivanco G. Epidemiologic study to evaluate the treatment of palmar-plantar erythrodysesthesia (PPE) in patients (pts) with ovarian cancer (OC) or metastatic breast cancer (MBC) treated with pegylated liposomal doxorubicin (PLD). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e12014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
115
|
Barriuso J, Mendiola M, Redondo A, Sánchez-Navarro I, Mariño-Enriquez A, Fresno-Vara JA, Perez E, Hernandez A, Espinosa E, Hardisson D. Angiogenesis-related gene profile to predict outcome to multimodal therapy in advanced ovarian carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
116
|
Mendiola M, Barriuso J, Redondo A, Sánchez-Navarro I, Mariño-Enriquez A, Madero R, Zamora P, De-Santiago J, Espinosa E, Hardisson D. Involvement of angiogenesis genes in pathologic response of advanced ovarian carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
117
|
Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol 2010; 118:88-92. [PMID: 20439111 DOI: 10.1016/j.ygyno.2010.03.012] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2010] [Revised: 03/18/2010] [Accepted: 03/19/2010] [Indexed: 10/19/2022]
Abstract
Ovarian cancer is the second most common gynecologic malignancy, and represents the fifth most common cause of cancer death in women in the United States. The age at diagnosis, extent of disease, success of primary surgery, and the histopathological features of the tumor are important prognostic markers. Epithelial ovarian carcinomas are classified into four major categories: serous, mucinous, endometrioid, and clear cell. Each subtypes of ovarian carcinoma are known to have different clinical characteristics and biological behaviour and response to chemotherapy. Molecular studies have supported for the notion that the different histological types of ovarian cancer likely represent histopathologically, genetically, and biologically distinct diseases. Microarray-based profiling technologies have provided an opportunity to simultaneously examine the relationship between thousands of genes and clinical phenotypes. In this review, we will summarise the current gene-expression profiles that address the classification of ovarian cancer into molecular subtypes with different outcomes.
Collapse
|
118
|
Barriuso J, Mendiola M, Redondo A, Mariño-Enriquez A, Madero R, Sanchez-Navarro I, Fresno-Vara JA, Gomez-Raposo C, Espinosa E, Hernandez-Cortes G, Santiago JD, Hernandez A, Jose BS, Feliu J, Gonzalez-Barón M, Hardisson D. Abstract 379: Predictive profile of pathological response in advanced ovarian carcinoma derived from angiogenesis-related genes. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Studies have consistently shown that the volume of residual disease remaining after cytoreductive surgery inversely correlates with survival. Women with optimally resected tumor have, on average, a 20-month improvement in median survival compared to those with suboptimal resection. It is difficult to predict which patients can be optimally debulked. CA 125 level and scoring imaging techniques have been used, however they were not enough accurate to obviate the initial surgical exploration. Several genes involved in angiogenesis proved to have prognosis capacity in advanced ovarian carcinoma. The aim of this study is to find model derived from angiogenesis genes to predict pathological response to treatment.
Material and Methods:
34 patients with III/IV FIGO stage ovarian cancer that underwent surgical cytoreduction and received a carboplatin plus paclitaxel chemotherapy regime were included. A second look laparotomy was performed in all the patients. Optimal debulking was defined as ≤1 cm (diameter) residual disease. RNAs were collected from formalin-fixed paraffin-embedded advanced ovarian carcinoma samples. Expression levels of 82 angiogenesis related genes were measured using quantitative real time polymerase chain reaction (qRT-PCR). A logistic regression method was used to build multiple models based on the significant genes in the univariate analysis. The accuracy of the models was evaluated using Receiver Operating Characteristic (ROC) curves. The Akaike Information Criterion based selection was used to find the most accurate one. And Leave-one-out Cross Validation (LOOCV) method was applied to avoid overoptimistic predictions.
Results:
The median age at diagnosis was 50 years (range, 35 to 79 years). All patients had advanced disease (FIGO stages III/IV). Most of them had FIGO stage III (27, 79.4%), grade 3 tumors (19, 55.9%), and serous histology (23, 67.6%). 20 patients (50.8%) achieved complete response after standard treatment. It was found an independent model able to predict any degree of response to therapy comprising 5 genes with an Area Under the Curve (AUC) of 0.950 (p<0.001). LOOCV was applied to avoid overfitting of the model, obtaining a corrected AUC of 0.846, 95%IC: 0,717-0,976.
Conclusions:
It is feasible to create a predictive profile for pathological response in AOC derived from genes involved in ovarian angiogenesis. Our profile could be used as predictive tool to enable clinicians to identify those high risk patients who will potentially benefit from alternative drug combinations. Nevertheless, the predictive value of our qRT-PCR based angiogenesis-related gene expression profile should be further evaluated in prospective studies of patients with AOC.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 379.
Collapse
|
119
|
Abraham J, Abreu P, Aglietta M, Ahn EJ, Allard D, Allekotte I, Allen J, Alvarez-Muñiz J, Ambrosio M, Anchordoqui L, Andringa S, Anticić T, Anzalone A, Aramo C, Arganda E, Arisaka K, Arqueros F, Asorey H, Assis P, Aublin J, Ave M, Avila G, Bäcker T, Badagnani D, Balzer M, Barber KB, Barbosa AF, Barroso SLC, Baughman B, Bauleo P, Beatty JJ, Becker BR, Becker KH, Bellétoile A, Bellido JA, Benzvi S, Berat C, Bergmann T, Bertou X, Biermann PL, Billoir P, Blanch-Bigas O, Blanco F, Blanco M, Bleve C, Blümer H, Bohácová M, Boncioli D, Bonifazi C, Bonino R, Borodai N, Brack J, Brogueira P, Brown WC, Bruijn R, Buchholz P, Bueno A, Burton RE, Busca NG, Caballero-Mora KS, Caramete L, Caruso R, Castellina A, Catalano O, Cataldi G, Cazon L, Cester R, Chauvin J, Chiavassa A, Chinellato JA, Chou A, Chudoba J, Clay RW, Colombo E, Coluccia MR, Conceição R, Contreras F, Cook H, Cooper MJ, Coppens J, Cordier A, Cotti U, Coutu S, Covault CE, Creusot A, Criss A, Cronin J, Curutiu A, Dagoret-Campagne S, Dallier R, Daumiller K, Dawson BR, de Almeida RM, De Domenico M, De Donato C, de Jong SJ, De La Vega G, de Mello Junior WJM, de Mello Neto JRT, De Mitri I, de Souza V, de Vries KD, Decerprit G, Del Peral L, Deligny O, Della Selva A, Delle Fratte C, Dembinski H, Di Giulio C, Diaz JC, Díaz Castro ML, Diep PN, Dobrigkeit C, D'Olivo JC, Dong PN, Dorofeev A, Dos Anjos JC, Dova MT, D'Urso D, Dutan I, Duvernois MA, Ebr J, Engel R, Erdmann M, Escobar CO, Etchegoyen A, Facal San Luis P, Falcke H, Farrar G, Fauth AC, Fazzini N, Ferrero A, Fick B, Filevich A, Filipcic A, Fleck I, Fliescher S, Fracchiolla CE, Fraenkel ED, Fröhlich U, Fulgione W, Gamarra RF, Gambetta S, García B, García Gámez D, Garcia-Pinto D, Garrido X, Gelmini G, Gemmeke H, Ghia PL, Giaccari U, Giller M, Glass H, Goggin LM, Gold MS, Golup G, Gomez Albarracin F, Gómez Berisso M, Gonçalves P, Gonzalez D, Gonzalez JG, Góra D, Gorgi A, Gouffon P, Gozzini SR, Grashorn E, Grebe S, Grigat M, Grillo AF, Guardincerri Y, Guarino F, Guedes GP, Hague JD, Halenka V, Hansen P, Harari D, Harmsma S, Harton JL, Haungs A, Hebbeker T, Heck D, Herve AE, Hojvat C, Holmes VC, Homola P, Hörandel JR, Horneffer A, Hrabovský M, Huege T, Hussain M, Iarlori M, Insolia A, Ionita F, Italiano A, Jiraskova S, Kadija K, Kaducak M, Kampert KH, Karova T, Kasper P, Kégl B, Keilhauer B, Keivani A, Kelley J, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Knapik R, Knapp J, Koang DH, Krieger A, Krömer O, Kruppke-Hansen D, Kuehn F, Kuempel D, Kulbartz K, Kunka N, Kusenko A, La Rosa G, Lachaud C, Lago BL, Lautridou P, Leão MSAB, Lebrun D, Lebrun P, Lee J, Leigui de Oliveira MA, Lemiere A, Letessier-Selvon A, Lhenry-Yvon I, López R, Lopez Agüera A, Louedec K, Lozano Bahilo J, Lucero A, Ludwig M, Lyberis H, Maccarone MC, Macolino C, Maldera S, Mandat D, Mantsch P, Mariazzi AG, Marin V, Maris IC, Marquez Falcon HR, Marsella G, Martello D, Martínez Bravo O, Mathes HJ, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mazur PO, McEwen M, Medina-Tanco G, Melissas M, Melo D, Menichetti E, Menshikov A, Meurer C, Micanović S, Micheletti MI, Miller W, Miramonti L, Mollerach S, Monasor M, Monnier Ragaigne D, Montanet F, Morales B, Morello C, Moreno E, Moreno JC, Morris C, Mostafá M, Mueller S, Muller MA, Mussa R, Navarra G, Navarro JL, Navas S, Necesal P, Nellen L, Nhung PT, Nierstenhoefer N, Nitz D, Nosek D, Nozka L, Nyklicek M, Oehlschläger J, Olinto A, Oliva P, Olmos-Gilbaja VM, Ortiz M, Pacheco N, Pakk Selmi-Dei D, Palatka M, Pallotta J, Palmieri N, Parente G, Parizot E, Parlati S, Parra A, Parrisius J, Parsons RD, Pastor S, Paul T, Pavlidou V, Payet K, Pech M, Pekala J, Pelayo R, Pepe IM, Perrone L, Pesce R, Petermann E, Petrera S, Petrinca P, Petrolini A, Petrov Y, Petrovic J, Pfendner C, Piegaia R, Pierog T, Pimenta M, Pirronello V, Platino M, Ponce VH, Pontz M, Privitera P, Prouza M, Quel EJ, Rautenberg J, Ravel O, Ravignani D, Redondo A, Revenu B, Rezende FAS, Ridky J, Riggi S, Risse M, Ristori P, Rivière C, Rizi V, Robledo C, Rodriguez G, Rodriguez Martino J, Rodriguez Rojo J, Rodriguez-Cabo I, Rodríguez-Frías MD, Ros G, Rosado J, Rossler T, Roth M, Rouillé-d'Orfeuil B, Roulet E, Rovero AC, Salamida F, Salazar H, Salina G, Sánchez F, Santander M, Santo CE, Santos E, Santos EM, Sarazin F, Sarkar S, Sato R, Scharf N, Scherini V, Schieler H, Schiffer P, Schmidt A, Schmidt F, Schmidt T, Scholten O, Schoorlemmer H, Schovancova J, Schovánek P, Schroeder F, Schulte S, Schüssler F, Schuster D, Sciutto SJ, Scuderi M, Segreto A, Semikoz D, Settimo M, Shadkam A, Shellard RC, Sidelnik I, Siffert BB, Sigl G, Smiałkowski A, Smída R, Snow GR, Sommers P, Sorokin J, Spinka H, Squartini R, Stasielak J, Stephan M, Strazzeri E, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Susa T, Sutherland MS, Swain J, Szadkowski Z, Tamashiro A, Tamburro A, Tapia A, Tarutina T, Taşcău O, Tcaciuc R, Tcherniakhovski D, Tegolo D, Thao NT, Thomas D, Tiffenberg J, Timmermans C, Tkaczyk W, Todero Peixoto CJ, Tomé B, Tonachini A, Travnicek P, Tridapalli DB, Tristram G, Trovato E, Tueros M, Ulrich R, Unger M, Urban M, Valdés Galicia JF, Valiño I, Valore L, van den Berg AM, Vázquez JR, Vázquez RA, Veberic D, Venters T, Verzi V, Videla M, Villaseñor L, Vorobiov S, Voyvodic L, Wahlberg H, Wahrlich P, Wainberg O, Warner D, Watson AA, Westerhoff S, Whelan BJ, Wieczorek G, Wiencke L, Wilczyńska B, Wilczyński H, Williams C, Winchen T, Winnick MG, Wundheiler B, Yamamoto T, Younk P, Yuan G, Yushkov A, Zas E, Zavrtanik D, Zavrtanik M, Zaw I, Zepeda A, Ziolkowski M. Measurement of the depth of maximum of extensive air showers above 10{18} eV. PHYSICAL REVIEW LETTERS 2010; 104:091101. [PMID: 20366976 DOI: 10.1103/physrevlett.104.091101] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2009] [Indexed: 05/29/2023]
Abstract
We describe the measurement of the depth of maximum, X{max}, of the longitudinal development of air showers induced by cosmic rays. Almost 4000 events above 10;{18} eV observed by the fluorescence detector of the Pierre Auger Observatory in coincidence with at least one surface detector station are selected for the analysis. The average shower maximum was found to evolve with energy at a rate of (106{-21}{+35}) g/cm{2}/decade below 10{18.24+/-0.05} eV, and (24+/-3) g/cm{2}/decade above this energy. The measured shower-to-shower fluctuations decrease from about 55 to 26 g/cm{2}. The interpretation of these results in terms of the cosmic ray mass composition is briefly discussed.
Collapse
|
120
|
Redondo A. [Peripheral nerve surgery in leprosy]. Neurochirurgie 2009; 55:421-6. [PMID: 19793599 DOI: 10.1016/j.neuchi.2009.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2009] [Accepted: 09/04/2009] [Indexed: 10/20/2022]
Abstract
Leprosy has nearly disappeared in France but continues to affect two million patients in the world. Involvement of the peripheral nerve must be identified and requires surgical treatment, which can provide good results for pain and function. The author reviews the most frequently affected peripheral nerves and reports her personal series, with surgery performed concomitantly with the medical treatment of the disease.
Collapse
|
121
|
Goutagny S, Abdennadher M, Faillot T, Bouccara D, Bozorg-Grayeli A, Redondo A, Sterkers O, Kalamarides M. Histoire naturelle des tumeurs spinales associées à la neurofibromatose type 2. Neurochirurgie 2009. [DOI: 10.1016/j.neuchi.2009.08.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
122
|
Xhumari A, Couvelard A, Redondo A, Kalamarides M. Long-term follow-up of an infratentorial primary paraganglioma: a case report. Br J Neurosurg 2009; 21:531-5. [PMID: 17852107 DOI: 10.1080/02688690701432448] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
We report a case of infratentorial primary paraganglioma for which we have a 10-year incomplete pretreatment clinical and radiological follow-up. Partial surgical removal followed by external radiotherapy resulted in stable disease at 6 years follow-up. We compare our patient's case with similar cases reported in the literature.
Collapse
|
123
|
Zarrouk V, Leflon -Guibout V, Vellin JF, Bouccara D, Redondo A, Fantin B. I-08 Évaluation de la place de la PCR ARN 16S dans le diagnostic des méningites post opératoires en chirurgie intracrânienne. Med Mal Infect 2009. [DOI: 10.1016/s0399-077x(09)74422-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
124
|
Espinosa E, Gámez A, Sánchez I, Pinto [, Hardisson D, Madero R, Zamora P, Redondo A, González Barón M, Fresno Vara J. A reduced qRT-PCR-based gene expression signature with prognostic value in early breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2030
Background: Gene profiling may improve prognostic accuracy in patients with early breast cancer, but this technology is not widely available. We used commercial assays for qRT-PCR to measure the expression of 83 genes previously found to determine breast cancer prognosis. The objective of our study was to develop a simple molecular signature predicting relapse in early breast cancer with positive hormonal receptors.
 Methods: 153 patients (age 29-82 years-old) with early breast cancer and a minimum follow-up of 5 years were included. All tumours were positive for hormonal receptors and 38% had positive lymph nodes; 64% of patients received adjuvant chemotherapy (with anthracycline if N+ or high-risk N0). RNA was isolated from tissue slices of formalin-fixed paraffin-embedded samples using the MasterPure RNA Purification Kit (Epicentre Biotech). qRT-PCR amplifications were performed with TaqMan Gene Expression Assays products in an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems). The reactions were carried out using the TaqMan Low Density Arrays (Applied Biosystems). A supervised analysis was done to identify a prognostic expression signature using BRB Array Tools software. Survival curves were derived from Kaplan-Meier estimates and compared by log-rank test. The association of gene expression and clinical variables with distant metastasis-free survival (DMFS) was analyzed by Cox regression models. SAS 9.1 software package was used for statistical analyses.
 Results: After a median follow-up of 92 months, 28% of patients relapsed. We defined an 8-gene prognostic signature. The distant metastasis-free survival at 5 years was calculated for this profile. DMFS was 97% -good risk- versus 60% -poor risk, HR 20.3 (95% CI 6.17-67.2), p<0.001. This gene expression profile was highly informative in identifying patients with distant metastasis, even when corrected for traditional prognostic factors in Cox multivariate analysis (HR 20, 95% CI 5.9-67.4). Performance was similar to that of three validated gene profiles. The validity of this signature was verified in an independent cohort obtained at the GEO database.
 Conclusions: This study identifies a new molecular signature with prognostic utility that outperforms traditional histopathologic prognostic factors. Our 8-gene qRT-PCR assay is suitable for analyzing routine formalin-fixed paraffin-embedded samples in the clinical setting.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2030.
Collapse
|
125
|
Abraham J, Abreu P, Aglietta M, Aguirre C, Allard D, Allekotte I, Allen J, Allison P, Alvarez-Muñiz J, Ambrosio M, Anchordoqui L, Andringa S, Anzalone A, Aramo C, Argirò S, Arisaka K, Armengaud E, Arneodo F, Arqueros F, Asch T, Asorey H, Assis P, Atulugama BS, Aublin J, Ave M, Avila G, Bäcker T, Badagnani D, Barbosa AF, Barnhill D, Barroso SLC, Baughman B, Bauleo P, Beatty JJ, Beau T, Becker BR, Becker KH, Bellido JA, Benzvi S, Berat C, Bergmann T, Bernardini P, Bertou X, Biermann PL, Billoir P, Blanch-Bigas O, Blanco F, Blasi P, Bleve C, Blümer H, Bohácová M, Bonifazi C, Bonino R, Brack J, Brogueira P, Brown WC, Buchholz P, Bueno A, Burton RE, Busca NG, Caballero-Mora KS, Cai B, Camin DV, Caramete L, Caruso R, Carvalho W, Castellina A, Catalano O, Cataldi G, Cazon L, Cester R, Chauvin J, Chiavassa A, Chinellato JA, Chou A, Chudoba J, Chye J, Clark PDJ, Clay RW, Colombo E, Conceição R, Connolly B, Contreras F, Coppens J, Cordier A, Cotti U, Coutu S, Covault CE, Creusot A, Criss A, Cronin J, Curutiu A, Dagoret-Campagne S, Daumiller K, Dawson BR, de Almeida RM, De Donato C, de Jong SJ, De La Vega G, Junior WJMDM, Neto JRTDM, De Mitri I, de Souza V, Del Peral L, Deligny O, Della Selva A, Fratte CD, Dembinski H, Di Giulio C, Diaz JC, Diep PN, Dobrigkeit C, D'Olivo JC, Dong PN, Dornic D, Dorofeev A, Dos Anjos JC, Dova MT, D'Urso D, Dutan I, Duvernois MA, Engel R, Epele L, Erdmann M, Escobar CO, Etchegoyen A, Luis PFS, Falcke H, Farrar G, Fauth AC, Fazzini N, Ferrer F, Ferrero A, Fick B, Filevich A, Filipcic A, Fleck I, Fracchiolla CE, Fulgione W, García B, Gámez DG, Garcia-Pinto D, Garrido X, Geenen H, Gelmini G, Gemmeke H, Ghia PL, Giller M, Glass H, Gold MS, Golup G, Albarracin FG, Berisso MG, Gonçalves P, do Amaral MG, Gonzalez D, Gonzalez JG, González M, Góra D, Gorgi A, Gouffon P, Grassi V, Grillo AF, Grunfeld C, Guardincerri Y, Guarino F, Guedes GP, Gutiérrez J, Hague JD, Halenka V, Hamilton JC, Hansen P, Harari D, Harmsma S, Harton JL, Haungs A, Hauschildt T, Healy MD, Hebbeker T, Hebrero G, Heck D, Hojvat C, Holmes VC, Homola P, Hörandel JR, Horneffer A, Hrabovský M, Huege T, Hussain M, Iarlori M, Insolia A, Ionita F, Italiano A, Kaducak M, Kampert KH, Karova T, Kasper P, Kégl B, Keilhauer B, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Knapik R, Knapp J, Koang DH, Krieger A, Krömer O, Kuempel D, Kunka N, Kusenko A, La Rosa G, Lachaud C, Lago BL, Lebrun D, Lebrun P, Lee J, de Oliveira MAL, Letessier-Selvon A, Leuthold M, Lhenry-Yvon I, López R, Agüera AL, Bahilo JL, Lucero A, García RL, Maccarone MC, Macolino C, Maldera S, Mancarella G, Manceñido ME, Mandat D, Mantsch P, Mariazzi AG, Maris IC, Falcon HRM, Martello D, Martínez J, Bravo OM, Mathes HJ, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mazur PO, McCauley T, McEwen M, McNeil RR, Medina MC, Medina-Tanco G, Melo D, Menichetti E, Menschikov A, Meurer C, Meyhandan R, Micheletti MI, Miele G, Miller W, Mollerach S, Monasor M, Ragaigne DM, Montanet F, Morales B, Morello C, Moreno JC, Morris C, Mostafá M, Muller MA, Mussa R, Navarra G, Navarro JL, Navas S, Necesal P, Nellen L, Newman-Holmes C, Newton D, Nhung PT, Nierstenhoefer N, Nitz D, Nosek D, Nozka L, Oehlschläger J, Ohnuki T, Olinto A, Olmos-Gilbaja VM, Ortiz M, Ortolani F, Ostapchenko S, Otero L, Pacheco N, Selmi-Dei DP, Palatka M, Pallotta J, Parente G, Parizot E, Parlati S, Pastor S, Patel M, Paul T, Pavlidou V, Payet K, Pech M, Pekala J, Pelayo R, Pepe IM, Perrone L, Pesce R, Petrera S, Petrinca P, Petrov Y, Pichel A, Piegaia R, Pierog T, Pimenta M, Pinto T, Pirronello V, Pisanti O, Platino M, Pochon J, Privitera P, Prouza M, Quel EJ, Rautenberg J, Redondo A, Reucroft S, Revenu B, Rezende FAS, Ridky J, Riggi S, Risse M, Rivière C, Rizi V, Roberts M, Robledo C, Rodriguez G, Martino JR, Rojo JR, Rodriguez-Cabo I, Rodríguez-Frías MD, Ros G, Rosado J, Roth M, Rouillé-d'Orfeuil B, Roulet E, Rovero AC, Salamida F, Salazar H, Salina G, Sánchez F, Santander M, Santo CE, Santos EM, Sarazin F, Sarkar S, Sato R, Scherini V, Schieler H, Schmidt A, Schmidt F, Schmidt T, Scholten O, Schovánek P, Schroeder F, Schulte S, Schüssler F, Sciutto SJ, Scuderi M, Segreto A, Semikoz D, Settimo M, Shellard RC, Sidelnik I, Siffert BB, Sigl G, Grande NSD, Smiałkowski A, Smída R, Smith AGK, Smith BE, Snow GR, Sokolsky P, Sommers P, Sorokin J, Spinka H, Squartini R, Strazzeri E, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Sutherland MS, Swain J, Szadkowski Z, Takahashi J, Tamashiro A, Tamburro A, Tarutina T, Taşcău O, Tcaciuc R, Thao NT, Thomas D, Ticona R, Tiffenberg J, Timmermans C, Tkaczyk W, Peixoto CJT, Tomé B, Tonachini A, Torres I, Travnicek P, Tripathi A, Tristram G, Tscherniakhovski D, Tuci V, Tueros M, Tunnicliffe V, Ulrich R, Unger M, Urban M, Galicia JFV, Valiño I, Valore L, van den Berg AM, van Elewyck V, Vázquez RA, Veberic D, Veiga A, Velarde A, Venters T, Verzi V, Videla M, Villaseñor L, Vorobiov S, Voyvodic L, Wahlberg H, Wahrlich P, Wainberg O, Walker P, Warner D, Watson AA, Westerhoff S, Wieczorek G, Wiencke L, Wilczyńska B, Wilczyński H, Wileman C, Winnick MG, Wu H, Wundheiler B, Yamamoto T, Younk P, Zas E, Zavrtanik D, Zavrtanik M, Zaw I, Zepeda A, Ziolkowski M. Observation of the suppression of the flux of cosmic rays above 4 x 10 (19) eV. PHYSICAL REVIEW LETTERS 2008; 101:061101. [PMID: 18764444 DOI: 10.1103/physrevlett.101.061101] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2008] [Indexed: 05/26/2023]
Abstract
The energy spectrum of cosmic rays above 2.5 x 10;{18} eV, derived from 20,000 events recorded at the Pierre Auger Observatory, is described. The spectral index gamma of the particle flux, J proportional, variantE;{-gamma}, at energies between 4 x 10;{18} eV and 4 x 10;{19} eV is 2.69+/-0.02(stat)+/-0.06(syst), steepening to 4.2+/-0.4(stat)+/-0.06(syst) at higher energies. The hypothesis of a single power law is rejected with a significance greater than 6 standard deviations. The data are consistent with the prediction by Greisen and by Zatsepin and Kuz'min.
Collapse
|